Cary Street Partners Investment Advisory LLC Buys 204 Shares of Novo Nordisk A/S (NYSE:NVO)

Cary Street Partners Investment Advisory LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,981 shares of the company’s stock after purchasing an additional 204 shares during the quarter. Cary Street Partners Investment Advisory LLC’s holdings in Novo Nordisk A/S were worth $412,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Pacific Center for Financial Services grew its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. Bell Investment Advisors Inc grew its holdings in Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. CNB Bank acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $26,000. Tyler Stone Wealth Management lifted its holdings in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. boosted its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on NVO shares. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average target price of $133.60.

View Our Latest Analysis on Novo Nordisk A/S

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $132.89 on Wednesday. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a market cap of $596.35 billion, a P/E ratio of 45.82, a P/E/G ratio of 2.05 and a beta of 0.43. The business’s 50 day moving average price is $127.78 and its 200 day moving average price is $114.41.

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Recommended Stories

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.